As of the latest Form 4 filed Jul 10, 2026.
What Heartflow, Inc. Common Stock insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 32 most recent filings for HTFL.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-10 | 2026-07-08 | WELDON WILLIAM C Director | MExercise | +17.1K | $8.33 | $143K | No | Form 4 ↗ |
| 2026-07-10 | 2026-07-08 | WELDON WILLIAM C, Director | MExercise | +17.1K | $8.33 | $143K | No | Form 4 ↗ |
| 2026-07-10 | 2026-07-08 | WELDON WILLIAM C, Director | MExercise | +17.1K | $8.33 | $143K | No | Form 4 ↗ |
| 2026-06-26 | 2026-06-24 | Farquhar John C.M. Chief Executive Officer | SSale | −38.9K | $35.00 | $1.36M | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Rogers Campbell Chief Medical Officer | MExercise | +10.0K | $2.22 | $22.2K | Yes (planned) | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Farquhar John C.M. Chief Executive Officer | SSale | −22.6K | $28.50 | $643K | Yes (planned) | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Rogers Campbell Chief Medical Officer | SSale | −9.22K | $28.34 | $261K | Yes (planned) | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Rogers Campbell, Chief Medical Officer | MExercise | +9.22K | $19.00 | $175K | Yes (planned) | Form 4 ↗ |
| 2026-05-13 | 2026-05-11 | Farquhar John C.M. Chief Executive Officer | SSale | −22.6K | $29.12 | $657K | Yes (planned) | Form 4 ↗ |
| 2026-05-08 | 2026-05-07 | Jones Marie L. Chief Accounting Officer | FTax | −82.00 | $29.98 | $2.46K | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-07 | Rogers Campbell Chief Medical Officer | FTax | −637.00 | $29.98 | $19.1K | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-07 | Verghese Vikram Chief Financial Officer | FTax | −473.00 | $29.98 | $14.2K | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-07 | Farquhar John C.M. Chief Executive Officer | FTax | −1.90K | $29.98 | $57.1K | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-06 | Jones Marie L. Chief Accounting Officer | FTax | −485.00 | $30.29 | $14.7K | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-06 | Rogers Campbell Chief Medical Officer | FTax | −1.63K | $30.29 | $49.5K | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-06 | Verghese Vikram Chief Financial Officer | FTax | −1.54K | $30.29 | $46.5K | No | Form 4 ↗ |
| 2026-05-08 | 2026-05-06 | Farquhar John C.M. Chief Executive Officer | FTax | −5.30K | $30.29 | $161K | No | Form 4 ↗ |
| 2026-04-30 | 2026-04-30 | Bain Capital Life Sciences Investors, LLC 10% owner | SSale | −56.2K | $30.05 | $1.69M | No | Form 4 ↗ |
| 2026-04-30 | 2026-04-30 | Bain Capital Life Sciences Investors, LLC, 10% owner | SSale | −893K | $29.18 | $26.0M | No | Form 4 ↗ |
| 2026-04-30 | 2026-04-29 | Bain Capital Life Sciences Investors, LLC, 10% owner | SSale | −797K | $29.37 | $23.4M | No | Form 4 ↗ |
| 2026-04-30 | 2026-04-28 | Bain Capital Life Sciences Investors, LLC, 10% owner | SSale | −254K | $30.51 | $7.75M | No | Form 4 ↗ |
| 2026-04-14 | 2026-04-10 | Farquhar John C.M. Chief Executive Officer | SSale | −22.6K | $26.72 | $603K | Yes (planned) | Form 4 ↗ |
| 2026-03-26 | 2026-03-24 | HealthCor Partners Management LP Director | JOther | −4.62M | — | — | No | Form 4 ↗ |
| 2026-03-26 | 2026-03-24 | Lightcap Jeffrey C Director | JOther | +206K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-23 | 2026-03-19 | Rogers Campbell Chief Medical Officer | SSale | −64.5K | $25.69 | $1.66M | Yes (planned) | Form 4 ↗ |
| 2026-03-23 | 2026-03-19 | Rogers Campbell, Chief Medical Officer | MExercise | +47.6K | $2.22 | $106K | Yes (planned) | Form 4 ↗ |
| 2026-03-23 | 2026-03-19 | Rogers Campbell, Chief Medical Officer | MExercise | +19.4K | $2.22 | $43.1K | Yes (planned) | Form 4 ↗ |
| 2026-03-20 | 2026-03-18 | Farquhar John C.M. Chief Executive Officer | SSale | −9.72K | $25.00 | $243K | Yes (planned) | Form 4 ↗ |
| 2026-03-12 | 2026-03-11 | BARABE TIMOTHY C Director | MExercise | +8.67K | $2.22 | $19.2K | No | Form 4 ↗ |
| 2026-03-12 | 2026-03-10 | Farquhar John C.M. Chief Executive Officer | SSale | −12.8K | $22.66 | $291K | Yes (planned) | Form 4 ↗ |
| 2026-03-12 | 2026-03-06 | Farquhar John C.M., Chief Executive Officer | AAward | +2.63K | $16.15 | $42.5K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-05 | Cullivan Julie A Director | SSale | −9.12K | $25.00 | $228K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also HTFL’s full analysis or the market-wide insider trading feed. The tabs above jump to HTFL’s other SEC data.
Source: SEC Form 4 filings for HTFL, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.